Kick-off for the network for therapeutic nucleic acids
innos officially launched the network for "Therapeutic Nucleic Acids" at a kick-off meeting in Dresden on April 24, 2025. The network aims to bring innovative therapeutic concepts based on oligonucleotides from research into clinical application more quickly.
innos officially launched the network for "Therapeutic Nucleic Acids" at a kick-off meeting in Dresden on April 24, 2025. The network aims to bring innovative therapeutic concepts based on oligonucleotides from research into clinical application more quickly.
A bridge between research and clinic
Therapeutic nucleic acids - including mRNA, silencing oligonucleotides, and other types of active substances - are considered promising options for treating diseases that have been difficult to treat. However, the path from the idea in the laboratory to the clinical study is complex: it presents researchers with challenges that go far beyond molecular biology issues, such as regulatory requirements, GMP-compliant production, or study design.
The new network comes in by creating interfaces between players along the entire value chain and thus accompanying the path from the therapeutic idea to clinical trials and practical application. In addition to drug development, device construction, analytics, production, and clinical facilities are also integrated into the network.
A broad range of applications - from rare diseases to oncology
Therapeutic nucleic acids play a huge role in treating genetic diseases, rare diseases (orphan diseases), cancer, and autoimmune disorders. They enable the targeted regulation of gene activity - for example by specifically "silencing" disease-causing genes - or the targeted production of therapeutic proteins in the body, as with mRNA vaccines. Above all, their great potential lies in the therapeutic approaches' high specificity and individualizability.
Stimuli for projects, collaborations, and new markets
The network will actively support its partners in implementing joint projects to bring innovative approaches to market maturity. At the same time, the exchange of knowledge is key to approaching new business areas and access to new markets.
The initiative also promises to strengthen Germany's position in the field of nucleic acid-based therapeutics in the long term.
Please read the following press release for further information on the network and its partner companies.
The Network
